Spark Therapeutics Announces Phase 1/2 Gene Therapy Trial for Hemophilia A

Note: The following is an edited version of a press release from Spark Therapeutics. Read the press release from Spark Therapeutics in it’s entirety here.

Spark Therapeutics has announced that its Phase 1/2 trial for the investigation of gene therapy for hemophilia A (factor VIII deficiency) has begun. This trial will initially be enrolling participants at the Children’s Hospital of Philadelphia (CHOP) with additional sites expected to open in the coming months.
Spark Therapeutics has two clinical research programs in hemophilia. SPK-9001 is an investigational gene therapy product for hemophilia B being developed in collaboration with Pfizer, and SPK-8011, an investigational gene therapy product for hemophilia A, is now in a Phase 1/2 trial. Read a past HFA Industry News update about SPK-9001 study here.